+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Evidence that Chronic Apomorphine Treatment Enhances 5-Hydroxytryptamine Metabolism in Brains of Normal and Neonatally Hyperthyroid Rats

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Daily injection of L-triiodothyronine (10 μg/100 g, s.c.) for 30 days to neonatal rats significantly enhanced the metabolism of 5-hydroxytryptamine as reflected by increased tryptophan hydroxylase activity and 5-hydroxyindoleacetic acid levels of certain discrete brain regions. However, neonatal L-triiodothyronine treatment produced no change in <sup>3</sup>H-5-hy-droxytryptamine uptake by crude synaptosomes. Chronic treatment with apomorphine (1 mg/ kg/day, s.c.) for 15 days, beginning from 15 days of age, increased tryptophan hydroxylase activity as well as 5-hydroxytryptamine and 5-hydroxyindoleacetic acid levels and blocked the uptake of <sup>3</sup>H-labelled serotonin in crude synaptosomes of normal and L-triiodothyronine-treated animals. Furthermore, apomorphine (which is known to indirectly stimulate 5-hy-droxytryptaminergic neurons) produced a greater increase in tryptophan hydroxylase and 5-hydroxyindoleacetic acid in the mid-brain region of neonatally hyperthyroid animals as compared to normal rats. These data indicate that excess thyroid hormone in early life not only increases the turnover of brain 5-hydroxytryptamine, but also enhances the sensitivity of dopamine receptor sites, thus amplifying the stimulating action of apomorphine. Our findings also suggest that thyroid hormone in early life advances the overall development of monoaminergic systems in the brain.

          Related collections

          Author and article information

          S. Karger AG
          26 March 2008
          : 29
          : 6
          : 399-405
          Department of Pharmacology, Faculty of Health Sciences, School of Medicine, University of Ottawa, Ottawa, Ont.
          122957 Neuroendocrinology 1979;29:399–405
          © 1979 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 7
          Original Paper


          Comment on this article